Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Sci. STKE, 31 August 2004
Vol. 2004, Issue 248, p. tw310
[DOI: 10.1126/stke.2482004tw310]


CANCER Gene Silencing in Leukemia?

About 15% of acute myeloid leukemia cases display a chromosomal translocation with high-level expression of leukemogenic AML1-ETO fusion proteins. AML1-ETO contains a conserved TAF4-homology domain (TAFH) for which in vivo function is unknown but that might be expected to complex with other transcription factors. Zhang et al. now show that the TAFH domain AML1-ETO, and nonleukemic factor ETO, associates with HEB protein, a transcription factor of the E protein family. The domain by which ETO interacts with E protein coincides with the site targeted by p300/CBP histone acetyltransferase. The association of HEB and ETO may sterically block p300/CBP recruitment in vivo and allow recruitment of negative cofactors, such as HDACs, for gene silencing of HEB-responsive promoters in leukemic cells.

J. Zhang, M. Kalkum, S. Yamamura, B. T. Chait, R. G. Roeder, E protein silencing by the leukemogenic AML1-ETO fusion protein. Science 305, 1286-1289 (2004). [Abstract] [Full Text]

Citation: Gene Silencing in Leukemia? Sci. STKE 2004, tw310 (2004).

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882